Hemostasis & Thrombosis

Disseminated Intravascular Coagulation: Clotting and Bleeding at the Same Time

A patient with septic shock develops oozing from every needle stick and IV site while, at the same time, their toes turn dusky black from microvascular clots — the paradox that defines disseminated intravascular coagulation (DIC). Mortality in overt DIC ranges from roughly 40% to 80% depending on the trigger, and it complicates about 30–50% of severe sepsis cases.

DIC is not a primary disease but an acquired, systemic consumptive coagulopathy: an underlying insult (sepsis, trauma, obstetric catastrophe, malignancy) drives uncontrolled activation of the coagulation cascade throughout the microvasculature. Widespread fibrin deposition causes ischemic organ damage, while the simultaneous consumption of platelets and clotting factors — plus reactive fibrinolysis — leaves the patient unable to stop bleeding. Clotting and bleeding, at once, from the same runaway process.

  • MechanismTissue-factor-driven systemic thrombin generation with factor/platelet consumption
  • Classic signSimultaneous oozing from puncture sites plus microvascular thrombosis (e.g. acral cyanosis, purpura fulminans)
  • Key labsLow platelets, low fibrinogen, prolonged PT/aPTT, markedly elevated D-dimer, schistocytes
  • Diagnostic toolISTH overt-DIC score ≥5 (platelets, PT, fibrinogen, D-dimer/FDP)
  • First-line treatmentTreat the underlying trigger; replace with platelets/FFP/cryoprecipitate if bleeding
  • Main complicationsMulti-organ failure from microthrombi and life-threatening hemorrhage

Interactive visualization

Press play, or step through manually. The visualization is yours to drive — try it before reading on.

Open visualization fullscreen ↗

Watch the 60-second explainer

A condensed visual walkthrough — narrated, captioned, under a minute.

What DIC Is and Why It Matters

Disseminated intravascular coagulation is an acquired syndrome of dysregulated hemostasis that is always secondary to an underlying disorder. It sits at the crossroads of thrombosis and hemorrhage: the coagulation system is activated so intensely and diffusely that it both clots the microvasculature and exhausts its own resources.

  • Sepsis (especially Gram-negative bacteremia) — the single most common trigger.
  • Trauma — crush injury, burns, head injury releasing brain thromboplastin.
  • Obstetric emergencies — abruptio placentae, amniotic fluid embolism, retained products, HELLP.
  • Malignancy — acute promyelocytic leukemia (APL) and mucin-secreting adenocarcinomas.
  • Snakebite, severe transfusion reactions, and heat stroke.

It matters because DIC is both a marker of severity and an independent driver of mortality. The microthrombi produce ischemic multi-organ dysfunction, while consumption leaves the patient one procedure away from catastrophic bleeding. Recognizing it early — and treating the cause — is what changes outcomes.

The Mechanism, Step by Step

The engine of DIC is tissue factor (TF), the physiologic initiator of coagulation. In DIC, TF is aberrantly and systemically exposed or expressed:

  • Trigger: Endotoxin and inflammatory cytokines (TNF-α, IL-1, IL-6) induce TF on monocytes and endothelium; trauma and obstetric events dump TF-rich material directly into the circulation.
  • Initiation: TF binds factor VIIa, activating the extrinsic pathway → factor Xa → a burst of thrombin (IIa) throughout the vasculature, not confined to a wound.
  • Fibrin deposition: Thrombin cleaves fibrinogen to fibrin, forming microthrombi that shear passing red cells into schistocytes (a microangiopathic hemolytic anemia).
  • Consumption: Platelets and factors (I, II, V, VIII) are used up faster than they are made; natural anticoagulants (antithrombin, protein C) are depleted, worsening the imbalance.
  • Secondary fibrinolysis: Plasmin degrades fibrin, generating D-dimer and fibrin degradation products (FDPs), which themselves impair platelet function — tipping the patient toward bleeding.

Clinical Presentation and Classic Signs

The hallmark is the coexistence of bleeding and thrombosis. Because DIC is always secondary, the picture is superimposed on a critically ill patient.

Bleeding manifestations (usually dominate acute DIC):

  • Diffuse oozing from venipuncture sites, IV lines, and surgical wounds — the classic bedside clue.
  • Petechiae, ecchymoses, mucosal bleeding, hematuria, GI hemorrhage.
  • Intracranial or pulmonary hemorrhage in severe cases.

Thrombotic manifestations (may dominate chronic/malignancy-associated DIC):

  • Acral cyanosis and digital/limb gangrene from microvascular occlusion.
  • Purpura fulminans — rapidly spreading retiform purpura with skin necrosis, classically in meningococcemia and severe protein C depletion.
  • End-organ ischemia: acute kidney injury, delirium, respiratory failure (ARDS), hepatic dysfunction.

Chronic DIC (e.g., Trousseau syndrome in adenocarcinoma) may present quietly with migratory thrombophlebitis and only subtle lab abnormalities.

Diagnosis: Tests, Scores, and Cutoffs

There is no single confirmatory test; DIC is a clinical-plus-laboratory diagnosis in the right context. The ISTH overt-DIC scoring system is the standard, applied only when an underlying disorder known to cause DIC is present.

  • Platelet count: >100 = 0, <100 = 1, <50 = 2 points.
  • Fibrin marker (D-dimer/FDP): no rise = 0, moderate = 2, strong = 3 points.
  • Prolonged PT: <3 s = 0, 3–6 s = 1, >6 s = 2 points.
  • Fibrinogen: >1 g/L = 0, <1 g/L = 1 point.

A total score ≥5 is compatible with overt DIC; <5 suggests non-overt DIC and warrants repeat testing. Supporting findings: schistocytes on peripheral smear, low haptoglobin, elevated LDH and indirect bilirubin (microangiopathic hemolysis), and low antithrombin. Trend the labs — a falling fibrinogen and platelet count over serial draws is more telling than any single value. In liver disease, a low factor VIII points to DIC rather than hepatic synthetic failure (factor VIII is made outside the liver).

Management at a Mechanism Level

The cardinal rule: treat the underlying cause — antibiotics and source control for sepsis, delivery/evacuation for obstetric DIC, all-trans retinoic acid (ATRA) for APL. Without removing the driver, replacement is futile.

Supportive/replacement therapy is guided by bleeding, not numbers alone:

  • Platelet transfusion — for active bleeding or platelets <10–20 ×10⁹/L.
  • Fresh frozen plasma (FFP) — replaces consumed factors when PT/aPTT are prolonged and the patient is bleeding.
  • Cryoprecipitate or fibrinogen concentrate — for fibrinogen <1.5 g/L, since fibrinogen is often the first factor exhausted.

Anticoagulation with therapeutic/prophylactic heparin is selective: reserved for thrombosis-predominant DIC (e.g., acral ischemia, Trousseau syndrome, purpura fulminans) — heparin potentiates antithrombin to blunt thrombin generation. Antifibrinolytics (tranexamic acid) are generally contraindicated because inhibiting fibrinolysis can promote fatal microthrombosis — the notable exception being fibrinolysis-predominant states like APL. Antithrombin and recombinant thrombomodulin have been studied but are not routine standard of care.

Distinguishing DIC from Its Mimics

Several disorders share thrombocytopenia and organ injury, so the discriminators matter.

  • Thrombotic thrombocytopenic purpura (TTP): a thrombotic microangiopathy from ADAMTS13 deficiency (<10%) causing platelet-VWF microthrombi. Unlike DIC, PT/aPTT and fibrinogen are normal — coagulation factors are not consumed. Do not delay plasma exchange chasing a DIC workup.
  • Liver failure: also prolongs PT and lowers platelets and fibrinogen, but factor VIII is normal or elevated (extra-hepatic synthesis), whereas it is low in DIC.
  • Heparin-induced thrombocytopenia (HIT): thrombosis with thrombocytopenia but normal coagulation studies and recent heparin exposure.
  • Vitamin K deficiency / warfarin: prolonged PT with normal fibrinogen, platelets, and D-dimer.

Key pitfalls: a single normal fibrinogen can be falsely reassuring because it is an acute-phase reactant — trend it. And never treat the number in isolation: a non-bleeding patient with abnormal labs may need no transfusion at all, only aggressive treatment of the underlying trigger.

DIC versus its main microangiopathic and coagulopathy mimics
FeatureDICTTP/HUS (TMA)Liver failure coagulopathy
PlateletsLow (consumed)Low (consumed)Low (splenic sequestration)
PT / aPTTProlongedNormalProlonged
FibrinogenLow (consumed)NormalLow (reduced synthesis)
D-dimer / FDPMarkedly elevatedNormal or mildly upMildly elevated
Factor VIIILow (consumed)NormalNormal or high (extra-hepatic)
Key distinguishing testISTH score, low fibrinogenADAMTS13 <10% (TTP)Normal factor VIII, clinical liver disease

Frequently asked questions

How can DIC cause bleeding and clotting at the same time?

A systemic trigger drives uncontrolled thrombin generation, so tiny clots (microthrombi) form throughout the small vessels and cause organ ischemia. That same runaway process consumes platelets and clotting factors and triggers secondary fibrinolysis, so once the reserves are exhausted the patient can no longer form clots at wounds — hence simultaneous thrombosis and hemorrhage.

What is the most common cause of DIC?

Sepsis, particularly Gram-negative bacteremia, is the most frequent trigger, complicating roughly 30–50% of severe sepsis. Other major causes include major trauma, obstetric emergencies (placental abruption, amniotic fluid embolism), and malignancies such as acute promyelocytic leukemia and mucin-secreting adenocarcinomas.

Which lab tests are used to diagnose DIC?

There is no single test; diagnosis combines the clinical setting with a panel: platelet count, PT, aPTT, fibrinogen, and D-dimer/FDP, plus a smear for schistocytes. The ISTH overt-DIC score sums points from platelets, D-dimer, PT prolongation, and fibrinogen; a score of 5 or more is compatible with DIC. Trending falling platelets and fibrinogen is often more useful than any single value.

What D-dimer and fibrinogen levels are expected in DIC?

D-dimer is typically markedly elevated because of extensive fibrin breakdown, while fibrinogen is low or falling because it is consumed. A fibrinogen below 1 g/L scores points on the ISTH scale, but remember fibrinogen is an acute-phase reactant, so an early value can look deceptively normal — repeat testing catches the downward trend.

Is heparin used to treat DIC?

Only selectively. Heparin (which potentiates antithrombin to reduce thrombin generation) is reserved for thrombosis-predominant DIC such as acral ischemia, purpura fulminans, or cancer-associated Trousseau syndrome. In bleeding-predominant DIC, anticoagulation can worsen hemorrhage, so the mainstays are treating the cause and transfusing platelets, FFP, and cryoprecipitate as needed.

How is DIC different from TTP?

TTP is a thrombotic microangiopathy caused by severe ADAMTS13 deficiency (activity <10%), producing platelet-VWF microthrombi. Crucially, in TTP the PT, aPTT, and fibrinogen are normal because coagulation factors are not consumed, whereas DIC prolongs the clotting times and lowers fibrinogen. Distinguishing them is urgent because TTP is treated with plasma exchange.